EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer

L Angelats, L Paré, C Rubio-Perez, E Sanfeliu, A González, E Seguí, G Villacampa, M Marín-Aguilera, S Pernas, B Conte, V Albarrán-Fernández, O Martínez-Sáez und 25 weitere

ESMO Open · 2025-01 · 10 (1) · 104109

DOI: 10.1016/j.esmoop.2024.104109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESMO Open, 2025-01. Verfasst von L Angelats und 36 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; In…. Hauptthemen laut MEDLINE: Breast Neoplasms, Longevity, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the influence of B-cell tumor infiltration on overall patient survival remains unclear. MATERIALS AND METHODS: This study explored the relationship between an antitumor immune response, measured by a 14-gene B-cell/immunoglobulin (IGG) signature, and mortality risk in 9638 breast cancer patients across three datasets. Associations with tumor subtype, stage, and age were examined. IGG was characterized using spatial GeoMx profiling and single-cell RNA sequencing, and its relationship with tertiary lymphoid structures (TLSs) was evaluated. The predictive value of each of the 14 IGG genes for B-cell receptor (BCR) and T-cell receptor (TCR) clonality and longevity was also assessed, along with its association with longevity in other cancer types. RESULTS: High IGG signature expression was significantly associated with a 41%-47% reduction in death risk in breast cancer survivors (P < 0.001), regardless of age, tumor stage, or subtype. Similar associations were observed in other cancers, including melanoma. In breast cancer, the IGG signature was significantly linked to overall survival without relapse in patients aged 41-70 years at diagnosis. Additionally, IGG expression correlated with the presence of TLSs and higher B- and T-cell polyclonality. A specific subset of seven IGG genes strongly correlated with BCR and TCR clonality, with predictive power for identifying clonality and improved longevity, especially when combining two of these genes. CONCLUSIONS: This study uncovers a significant link between immune gene expression in tumors and extended longevity in breast cancer survivors, even in the absence of recurrence. The IGG signature, particularly its key gene subset, emerges as a powerful marker of sustained antitumor immunity and overall patient fitness. These findings pave the way for personalized treatment strategies that enhance both survival and long-term health outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLongevityLymphocytes, Tumor-InfiltratingHumansFemaleMiddle AgedAgedAdultImmunoglobulin GB-LymphocytesNeoplasm Recurrence, Local

Stichwörter der Autor:innen

breast cancerclonalityimmune gene expressionlongevity

Substanzen

Immunoglobulin G

Autor:innen und Institutionen

  • Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Ba…
  • Reveal Genomics, Barcelona, Spain.
  • Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain; Immunogenetics and Immunotherapy in Autoinflammatory and Immune Responses, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona,…
  • Statistics Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Institut Català d'Oncologia Medical Oncology, Breast Unit Barcelona, Barcelona, Spain.

Förderung

  • NCI NIH HHS

Zitieren

APA

Angelats, L., Paré, L., Rubio-Perez, C., Sanfeliu, E., González, A., Seguí, E., Villacampa, G., Marín-Aguilera, M., Pernas, S., Conte, B., Albarrán-Fernández, V., Martínez-Sáez, O., Aguirre, Á., Galván, P., Fernandez-Martinez, A., Cobo, S., Rey, M., Martínez-Romero, A., Walbaum, B., …, & Brasó-Maristany, F. (2025). Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. ESMO Open, 10(1), 104109. https://doi.org/10.1016/j.esmoop.2024.104109

Vancouver

Angelats L, Paré L, Rubio-Perez C, Sanfeliu E, González A, Seguí E, et al. Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer. ESMO Open. 2025;10(1):104109. doi:10.1016/j.esmoop.2024.104109

BibTeX
@article{Angelats2025,
  author = {Angelats, L and Paré, L and Rubio-Perez, C and Sanfeliu, E and González, A and Seguí, E and Villacampa, G and Marín-Aguilera, M and Pernas, S and Conte, B and Albarrán-Fernández, V and Martínez-Sáez, O and Aguirre, Á and Galván, P and Fernandez-Martinez, A and Cobo, S and Rey, M and Martínez-Romero, A and Walbaum, B and Schettini, F and Vidal, M and Buckingham, W and Muñoz, M and Adamo, B and Agrawal, Y and Guedan, S and Pascual, T and Agudo, J and Grzelak, M and Borcherding, N and Heyn, H and Vivancos, A and Parker, J S and Villagrasa, P and Perou, C M and Prat, A and Brasó-Maristany, F},
  title = {Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer},
  journal = {ESMO Open},
  year = {2025},
  volume = {10},
  number = {1},
  pages = {104109},
  doi = {10.1016/j.esmoop.2024.104109}
}
Kostenlos starten →